These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23821844)

  • 1. [Osteoporosis in men].
    Biver E; Uebelhart B
    Rev Med Suisse; 2013 Jun; 9(390):1260-4. PubMed ID: 23821844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Androgen deprivation therapy for prostate cancer and osteoporotic risk].
    Cortet B; Lartigau E; Caty A; Moulinier F; Staerman F; Villamizar-Vesga J; Villers A
    Prog Urol; 2012 Sep; 22 Suppl 2():S31-8. PubMed ID: 23098788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
    James H; Aleksic I; Bienz MN; Pieczonka C; Iannotta P; Albala D; Mariados N; Mouraviev V; Saad F
    Urology; 2014 Jul; 84(1):164-8. PubMed ID: 24976229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of osteoporosis in men on androgen deprivation therapy.
    Adler RA
    Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
    Wadhwa VK; Weston R; Parr NJ
    BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.
    Poon Y; Pechlivanoglou P; Alibhai SMH; Naimark D; Hoch JS; Papadimitropoulos E; Hogan ME; Krahn M
    BJU Int; 2018 Jan; 121(1):17-28. PubMed ID: 28921820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
    BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S; DjeDjos S; Alferos G; Deprisco C
    Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.
    Alibhai SM; Duong-Hua M; Cheung AM; Sutradhar R; Warde P; Fleshner NE; Paszat L
    J Urol; 2010 Sep; 184(3):918-23. PubMed ID: 20643458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing osteoporotic fractures in older people.
    McCloskey E
    Practitioner; 2011 Jan; 255(1736):19-22, 2-3. PubMed ID: 21370710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
    Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F
    Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
    Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
    J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.